Role of follow-up blood cultures for Gram positives
Valeria Fabre
Detection of bacteria depends on:
Volume of blood and number of sets - should aim 40ml in 4 bottles (2 sets)
About 20% of GP bactermia are persistent. Mostly S. aureus. Strep not persistent. Wiggers BMC ID 2016
Persistance in SAB may occur in up to 40% of cases
Minejima CID 2020 mentioned again. @BradSpellberg
Risk factors for prolonged SAB - MRSA, endovascular source, ICU
Bacteremia of ≥3 days independent predictor of 30-day mortality
Delay in initiation of effective therapy NOT associated with prolongation. But delay in source control was. Delay in source control assoc with higher mortality
Kuhel Lancet ID 2020
Also found assoc with bacteremia duration and mortality
Lack of source control increased 90d mortality. Even then, pSAB despite removal of suspected focus had increased mortality (17 to 34%)
2nd day of bacteremia after active therapy best distinguished those who died vs survivors
Skip phenomenon - BC intermittently positive
More common in immunocompromised, those with cardiac devices, no diff in mortality
Australian study (Jim Stewart) of 1017 cases. Skip occurred in 13%. SP assoc with relapse. More common with MRSA. 2 sets of BC increased sens
New topic:
Persistent Strep bacteremia
159 non-staph IE, all strep. NO cases persistent bacteremia
314 cases Strep. 12% with IE. Follow-up BC+ in 3%. No difference in outcomes
20% of Enterococcus BSI persistent
Especially if on prostehtic valves
DENOVA scare to determine risk of IE
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Gianella CMI 2020. Lower mortality in those who had follow-up BC done -> 2 fold reduction.
Maskarinec CMI 2020. 1702 patients. FUBC in 68%. 20% FUBC persistently positive. Higher mortality if no FUBC. If done, FUBC+ higher mortality
I haven't read the studies, but do wonder about both immortal time bias and bias by indication in these studies. Is there something systematically different in those who do get FUBC?
Amipara EClinicalMedicine 2021
766 patients. Excluded if died within 72h. Propensity score adjustment
If FUBC not done, higher mortality. About 0.5 hazard ratio.
So the above 3 studies, consistently found 2 fold decline in mortality if FUBC done.
Infliximab - about 500 in active and placebo arms; no diff in time to recovery. 41% lower odds of day 28 mortality, 32% higher odds of clinical status at day 14.
No diff in adverse events
Abatacept - about 500 in active and placebo; no diff in time to recovery, Reduced odds of day 28 mortality. No diff in adverse events, with slightly higher bacterial infections (not stats sig).
Getting ready for Clinical Controversies in treatment of S. aureus bacteremia. #IDWeek2022
Increasing recognition that 'persistent' bacteremia should probably be earlier rather than later. Each day longer, associated with increased metastatic complications and mortality.
What is best treatment? ASP or cefazolin? Issues of increased toxicity vs cefazolin inoculum effect.
>>> we need to test in a clinical trial
If still BC+ at 5 days?
No routine role for combination antibiotics - no benefit with rifampin, daptomycin, aminoglycosides in trials
Debating role of vancomycin for MRSA at #IDWeek2022.
Dr Wagner argues that increasing duration of MRSA bacteraemia associated with poorer outcomes (mortality).
I accept this.
BUT, therapeutically reducing duration of bacteraemia has not been associated with improved mortality.
Duration of bacteremia is a SURROGATE. Although logical and biologically plausible that reducing duration of bacteremia with a particular antibiotic (vs another) should improve the outcome we care about (mortality), this has not yet been demonstrated.
Cites 43% of patients with trough-based dosing develop AKI.
We didn't find this in CAMERA2. Almost all on vanc and trough-based dosing. In control arm only 6% developed AKI. jamanetwork.com/journals/jama/…
Yes, that was in the context of a clinical trial. But 6% is far from 43%